MedAI newsletter

Archives
Log in
Subscribe
November 20, 2026

MedAI Update: Friday, November 20, 2026

MedAI Update: Daily Digest, Friday, November 20, 2026 AI in medicine policy, explained. Five stories a day, each summarized in plain language.

PART 1: QUICK SUMMARY 1. FDA oversight unanswered for Utah AI prescribing pilots 2. Healthcare AI monitoring gaps raise breach risk 3. Coreline Soft wins 13th FDA clearance for aorta AI 4. Epic headline promises AI record access; details paywalled 5. NY enforcer headline flags AI agent liability risk

PART 2: THE DETAILS

FDA oversight unanswered for Utah AI prescribing pilots Source: https://www.medicaldaily.com/hhs-roadmap-utah-ai-prescribing-fda-oversight-481415 The text says a federal clinical AI roadmap leaves unanswered whether the FDA oversees Utah pilots that let AI refill prescriptions and, in one pilot, write them. It does not provide details about the pilots, the roadmap, or any federal decision. Why it matters: The open question matters because it leaves uncertainty about which regulator, if any, would oversee AI tools that can issue prescriptions.

Healthcare AI monitoring gaps raise breach risk Source: https://www.healthcaredive.com/news/healthcare-ai-cybersecurity-monitoring/875171/ A DNSFilter report says healthcare organizations face cybersecurity risks from AI systems they do not carefully monitor, and providers are not doing enough to ensure those tools work properly. In the survey, six in 10 healthcare respondents relied on AI and SaaS vendors to alert them to security incidents, above the 43% average in other sectors, while 23% relied on employees to report such incidents. Why it matters: The gap between AI adoption and monitoring can heighten breach risk and threaten the reliability of care, though the healthcare findings come from a small survey sample.

Coreline Soft wins 13th FDA clearance for aorta AI Source: https://www.koreabiomed.com/news/articleView.html?idxno=33922 Coreline Soft said it received FDA 510(k) clearance for AVIEW Aorta Metrics, AI software that measures aortic diameter on chest CT images, bringing its total FDA 510(k) clearances to 13. The company says its AVIEW chest CT platform also measures lung nodules, emphysema, COPD, coronary artery calcium and interstitial lung abnormality and is used at more than 500 medical institutions in 19 countries. Why it matters: The clearance adds a cleared AI measurement tool to a platform marketed for extracting multiple disease findings from a single chest CT scan.

Epic headline promises AI record access; details paywalled Source: https://www.statnews.com/2026/11/19/epic-defends-competitive-practices-promises-ai-access-health-tech/ A STAT Health Tech item is headlined as Epic defending its competitive practices and promising access to records for AI agents. The available text is largely a paywall and does not include details of Epic's practices, the access promise, or the AI agents involved. Why it matters: The headline signals a debate over AI access to health records and competition in health IT, but the available text does not explain the terms.

NY enforcer headline flags AI agent liability risk Source: https://www.law360.com/productliability/articles/2551848?utm_source=rss&utm_medium=rss&utm_campaign=section The available text for a Law360 article is headlined "NY Enforcer Flags Product Liability Risk For AI Agent Makers" but contains only site navigation and no article body. It does not identify the enforcer, the AI agent makers, or the liability risk described. Why it matters: The headline points to a possible product liability issue for AI agent developers, but without article text the scope and legal significance are unknown.

This newsletter is information, not medical advice.

Subscribe to get this digest each morning: https://buttondown.com/vote

Don't miss what's next. Subscribe to MedAI newsletter :
Older → MedAI Update: Thursday, November 19, 2026
Powered by Buttondown, the easiest way to start and grow your newsletter.